Why doctors choose to invest in a company like Galeon ?

For a long time, a doctor's role was clear: to treat, to teach, to train, sometimes to innovate. Investing in tech startups is a new part of the equation.

In recent years, the boundaries have been shifting. Artificial intelligence is making its way into hospital departments, digital tools are playing an increasingly important role in patient care, and more and more healthcare professionals are taking an interest in the companies shaping this transformation.

Not everyone takes the leap. Many never will. A few choose to become shareholders in projects they consider worthwhile — because they see an investment opportunity, or because they share a vision, often both.

So what drives a doctor to invest in a company like Galeon?

A different perspective on innovation

A seasoned investor analyzes a market, a business model, a management team, or growth prospects — usually with a fairly short time horizon of a few years.

In the healthcare market, a doctor sees things differently. They know that a consumer app could never hold up in a hospital setting. The complexity of the field, and the stakes involved in outcomes, make healthcare a particularly hard market to break into: long sales cycles, demanding users, risks to patient health.

Field experience doesn't automatically make a doctor an investor. But it does give them a very concrete understanding of the problems certain companies are trying to solve.

When a healthcare professional decides to invest in a HealthTech company, they're not just investing in a technology or a business plan alone.

Investing in a conviction… Without forgetting the risks

It would be reductive to think doctors invest purely out of activism. Like any investor, they invest to create value — and to capture a share of it.

They also know that investing in a healthcare startup — generally unlisted — carries risks: partial or total loss of capital, lack of liquidity, a long investment horizon, uncertainties tied to the company's development.

That reality doesn't disappear just because the company operates in the healthcare sector.

The difference may lie elsewhere. Doctors can have an intimate understanding of the problem a company is trying to solve. That gives them a perspective few investors have.

They don't just read a business plan. They test it against their own experience.

The hospital Is changing. So are expectations.

For years, hospital digitization essentially meant replacing paper. Today, expectations are far more sophisticated.

Institutions want software that can communicate with one another, simplify care pathways, make better use of medical data, and prepare for the next generation of AI-based tools.

At the same time, regulatory requirements are tightening. Cybersecurity, data sovereignty, and interoperability now sit at the heart of hospital leadership decisions.

For a doctor following these developments, investing in a digital health company can also be a way of supporting this transformation — not because it's perfect, but because they believe it's heading in a direction they consider meaningful.

Why Galeon?

Galeon was born from an observation shared by many healthcare professionals: the electronic health record (EHR) has become one of the hospital's most important tools — and also one of the hardest to evolve.

The company's ambition is to offer a new generation of EHR, built around structured data, interoperability, and an architecture designed to support future AI use cases, all while keeping data within healthcare institutions.

This vision can naturally resonate with certain doctors.

That doesn't mean everything is simple. Deploying a new patient record system in a large hospital remains one of the most complex digital projects there is.

Every institution has its own organization, habits, and constraints. The early phases of a rollout inevitably require adjustments, user feedback, and close collaboration between hospital teams and the software provider.

Building an EHR is a long-term undertaking. Starting from a blank page, the work is estimated to take 10 irreducible years.

Supporting a vision rather than a promise

Investment is often presented as a calculation. In reality, it's also a matter of conviction.

Some choose to invest in renewable energy. Others in industry, defense, or biotech. The same holds true for digital health.

When a doctor invests in a company like Galeon, they may do so because they believe the cause deserves support. Because they believe it's possible to build tools better suited to caregivers' needs. Because they want to see European solutions emerge in a strategic sector.

Conviction guarantees nothing, but it is what fuels the ambition behind the project.

A company can have a relevant vision without succeeding in its development. An investment may never deliver the hoped-for result.

That is precisely why investing in an unlisted company must always be a personal, well-considered decision, compatible with one's own risk profile.

In Conclusion

The real question isn't "why do some doctors choose to invest in Galeon?"

It's more specific than that: why do healthcare professionals decide to fund the tools they want to use tomorrow?

The answer doesn't lie in a business plan alone. It sits at the intersection of hands-on experience, a vision of the hospital of the future, and the willingness to take on investment risk — fully aware of both the risks and the opportunity.

‍